BJMO - 2021, issue 3, march 2021
Dan Truc Nguyen , Stéphane Holbrecht , Soizic Garaud
Introduction: Immune checkpoint inhibitors (ICI) are becoming a cornerstone of therapies for many cancers. However, a new class of side effects has emerged, namely immune-related adverse events (irAEs). Many studies have suggested a potential relationship between irAEs and benefit of ICI, but little is known about the mechanisms underlying toxicity and antitumor efficacy.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
